An informational overview of publicly available disclosures for Magnesium Niacinamide Relief (MagnesiumFreeze) — covering ingredients, company policies, and what consumers researching topical nerve ...

In Q4 2025, approximately 5.0 million shares were issued under the ATM Program for gross proceeds of approximately $101.1 million at an average share price of $20.15, and resulting in the full ...

DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today ...

About Olema Oncology Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and ...

Mechelen, Belgium; February 19, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Dr. Paulo Fontoura as Non-Executive Independent ...

RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene or CAN-2409) for intermediate- to high-risk localized ...

SAN CLEMENTE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial ...

Nautilus’ management is scheduled to participate in a fireside chat on Monday, March 2, 2026, at 10:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation ...

IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management ...

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and ...

Month over month sales of MangoRx’s injectable TRT treatment program have increased 336% since launching in mid-December while at the same time reducing customer acquisition costs by 54%.

Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, February 26 from 10:40 AM to 11:05 AM ET. Fortney and Dov Goldstein, MD, CFO, will participate in ...